Generation Bio Co. (GBIO)
After hours:
| Previous close | 2.7800 |
| Open | 2.7500 |
| Bid | 2.7900 x 200 |
| Ask | 2.8300 x 200 |
| Day's range | 2.7000 - 2.8400 |
| 52-week range | 0.8600 - 6.9800 |
| Volume | |
| Avg. volume | 244,546 |
| Market cap | 186.136M |
| Beta (5Y monthly) | 2.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.9600 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.50 |
GlobeNewswireGeneration Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 12:45 p.m. ET. A live webcast of the presentation will be available on the investor section of the company’s w
- GuruFocus.com
Generation Bio Co Reports Full Year and Q4 2023 Financial Outcomes
Advancements in Genetic Medicine Platforms Highlighted Amid Financial Review
ZacksGeneration Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -29.27% and 5.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
